Drugs / BOW015
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02683564 | Feb 2016 → Jul 2017 | rheumatoid arthritis | Epirus Biopharmaceuticals (Switzerland) GmbH | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOW015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02683564 ↗ |
| Action | Inhibit | “monoclonal antibody against TNF-alpha” NCT02683564 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody against TNF-alpha” NCT02683564 ↗ |
| Route | Intravenous | “as intra venous infusion” NCT02683564 ↗ |